GO:0070996 type 1 melanocortin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070996 (type 1 melanocortin receptor binding) is a molecular function describing the binding of a ligand to the type 1 melanocortin receptor (MC1R), a G protein-coupled receptor.
• The term is defined by QuickGO as binding to a type 1 melanocortin receptor, with the synonym type 1 melanocortin receptor ligand.
• Key ligands include alpha-melanocyte-stimulating hormone (alpha-MSH), ACTH, and synthetic analogs such as NDP-MSH, which bind MC1R to trigger downstream signaling.
• MC1R binding is critical in melanocytes for pigmentation, DNA repair, and antioxidant defense, and its dysfunction is linked to melanoma and other cancers.
• In the brain, MC1R binding by NDP-MSH reduces neuroinflammation and blood-brain barrier disruption via CREB/Nr4a1/NF-kB signaling.
• Research on this term employs CRISPR knockout, point mutation, knock-in, and overexpression models to dissect MC1R signaling in disease contexts.
Description
GO:0070996, type 1 melanocortin receptor binding, is a molecular function term in the Gene Ontology that describes the selective interaction between a ligand and the type 1 melanocortin receptor (MC1R). MC1R is a G protein-coupled receptor primarily expressed on melanocytes, where it regulates pigmentation and cytoprotective responses. This binding event is the first step in a signaling cascade that influences diverse physiological processes, from skin pigmentation to neuroinflammation. Researchers study this term to understand how extracellular signals are translated into cellular responses and to identify therapeutic targets for melanoma, obesity, and inflammatory conditions. The availability of specific ligands, such as NDP-MSH and alpha-MSH, has enabled detailed mechanistic studies. Moreover, genetic variation in MC1R is associated with melanoma risk and pigmentation phenotypes, underscoring the clinical relevance of this binding interaction.
type 1 melanocortin receptor binding At A Glance
| GO ID | GO:0070996 |
|---|---|
| GO term | type 1 melanocortin receptor binding |
| Ontology | molecular_function |
| Synonym | type 1 melanocortin receptor ligand |
| Major function | Binding to MC1R, initiating signaling cascades involved in pigmentation, inflammation, and energy homeostasis |
| Major ligands | alpha-MSH, ACTH, NDP-MSH, and other melanocortin peptides |
| Receptor | MC1R (melanocortin 1 receptor), a G protein-coupled receptor |
| Associated diseases | Melanoma, obesity, neuroinflammation |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, binding assays, signaling assays |
What Is GO:0070996?
According to the Gene Ontology, GO:0070996 (type 1 melanocortin receptor binding) is defined as the binding to a type 1 melanocortin receptor. This molecular function is carried out by ligands that physically interact with MC1R, a member of the melanocortin receptor family. The synonym 'type 1 melanocortin receptor ligand' reflects the role of the binding partner. This term does not describe downstream signaling events but specifically the recognition and binding event itself, which is a prerequisite for receptor activation.
Why Is type 1 melanocortin receptor binding Important in Cell Biology?
Understanding type 1 melanocortin receptor binding is crucial because it is the entry point for MC1R-mediated signaling, which plays a central role in melanocyte biology, pigmentation, and protection against UV-induced DNA damage. Dysregulation of this binding event is implicated in melanoma progression, and MC1R variants are known melanoma predisposition alleles. Beyond pigmentation, MC1R binding in the central nervous system has anti-inflammatory effects, as shown by NDP-MSH reducing neuroinflammation after intracerebral hemorrhage. Additionally, the melanocortin pathway, including MC1R, is linked to obesity and metabolic disorders, with mutations in GNAS affecting melanocortin signaling. Therefore, studying this binding function provides insights into cancer, neuroinflammation, and metabolic diseases, and informs the development of targeted therapies.
• MC1R binding regulates melanin synthesis and pigmentation, affecting skin cancer risk.
• It mediates anti-inflammatory and neuroprotective effects in the brain.
• MC1R is a target for melanoma imaging and therapy using radiolabeled ligands.
• Binding affinity and specificity determine the efficacy of melanocortin-based drugs.
• Genetic variants in MC1R alter binding and signaling, influencing melanoma predisposition.
• The melanocortin pathway is involved in energy homeostasis and obesity.
• MC1R binding activates CREB and NF-kB pathways, impacting cell survival and inflammation.
• Single-cell profiling of MC1R-inhibited melanocytes reveals transcriptional changes relevant to therapy.
• ACTH binding to MC1R (and MC2R) is important for adrenal function.
• Understanding binding mechanisms aids in designing selective ligands for MC1R versus other melanocortin receptors.
What Happens During type 1 melanocortin receptor binding?
Ligand recognition and binding
In simple terms: A signaling molecule docks onto the MC1R receptor on the cell surface.
The binding event begins when a melanocortin peptide, such as alpha-MSH or NDP-MSH, recognizes and binds to the extracellular domain of MC1R. This interaction is highly specific, involving electrostatic and hydrophobic contacts. NDP-MSH, a synthetic analog, binds MC1R with high affinity and has been used to study receptor activation. The binding triggers conformational changes in the receptor, leading to G protein coupling and downstream signaling.
Receptor activation and G protein coupling
In simple terms: Once the ligand binds, the receptor changes shape and activates an intracellular G protein.
Upon ligand binding, MC1R undergoes a conformational shift that allows it to act as a guanine nucleotide exchange factor for the Gs protein. This leads to the activation of adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream targets including CREB. This cascade is central to melanocyte proliferation, melanin production, and cytoprotection.
Downstream signaling and gene expression
In simple terms: The signal travels to the nucleus and turns genes on or off.
Activated CREB translocates to the nucleus and promotes the transcription of genes involved in pigmentation (e.g., MITF, TYR) and survival. Additionally, MC1R signaling can modulate the NF-kB pathway, reducing inflammatory responses. In a mouse model of intracerebral hemorrhage, NDP-MSH binding to MC1R ameliorated neuroinflammation and blood-brain barrier disruption through the CREB/Nr4a1/NF-kB pathway. This demonstrates that MC1R binding can have anti-inflammatory effects in the central nervous system.
Regulation and desensitization
In simple terms: The cell can turn off the signal to prevent overstimulation.
After prolonged stimulation, MC1R can be desensitized via phosphorylation by G protein-coupled receptor kinases (GRKs) and recruitment of beta-arrestin, leading to receptor internalization. This negative feedback prevents excessive signaling. Additionally, MC1R expression levels and availability of ligands regulate the overall activity. The melanocortin system is also influenced by other proteins such as agouti signaling protein (ASIP), which acts as an antagonist.
Key Genes Involved in GO:0070996 type 1 melanocortin receptor binding
The following genes and proteins are central to type 1 melanocortin receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MC1R | Receptor for melanocortin peptides; mediates pigmentation and inflammation | Target for melanoma therapy and pigmentation studies |
| POMC | Precursor of alpha-MSH, ACTH, and other melanocortins | Source of endogenous ligands for MC1R |
| ASIP | Antagonist of MC1R; regulates pigmentation | Modulates MC1R binding and signaling |
| CREB1 | Transcription factor activated downstream of MC1R | Mediates gene expression changes |
| NR4A1 | Nuclear receptor involved in anti-inflammatory signaling | Part of MC1R-mediated neuroprotection |
| NFKB1 | Transcription factor regulating inflammation | Inhibited by MC1R signaling |
| GNAS | G protein alpha subunit coupled to MC1R | Mutations affect melanocortin signaling in obesity |
| MITF | Master regulator of melanocyte development and pigmentation | Downstream target of MC1R signaling |
| TYR | Tyrosinase, key enzyme in melanin synthesis | Induced by MC1R activation |
| MC4R | Related melanocortin receptor involved in energy homeostasis | Contrasts with MC1R in ligand specificity |
| MC2R | ACTH receptor in adrenal cortex | Shares ACTH ligand with MC1R |
| PKA | Protein kinase A, downstream effector of cAMP | Mediates MC1R signaling |
| ARRB1 | Beta-arrestin 1, involved in receptor desensitization | Regulates MC1R internalization |
| GRK2 | G protein-coupled receptor kinase 2 | Phosphorylates activated MC1R |
| SLC45A2 | Pigmentation gene, interacts with MC1R pathway | Modifies melanoma risk |
| OCA2 | Pigmentation gene, associated with MC1R variants | Affects pigmentation phenotypes |
How Is type 1 melanocortin receptor binding Regulated?
The binding of ligands to MC1R is regulated at multiple levels. Ligand availability is controlled by the expression and processing of POMC, which yields alpha-MSH and ACTH. Antagonists such as ASIP compete for MC1R binding, modulating signaling. Receptor levels are regulated by transcription factors like MITF and by post-translational modifications. Desensitization involves GRK-mediated phosphorylation and beta-arrestin recruitment, leading to internalization. Additionally, GNAS mutations can alter downstream cAMP signaling, affecting the pathway's output. In neurons, MC4R constitutive activity inhibits L-type calcium channels, indicating cross-talk between melanocortin receptors.
type 1 melanocortin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MC1R | Melanoma, pigmentation disorders | CRISPR knockout in melanoma cell lines; point mutation knock-in in melanocytes |
| POMC | Obesity, adrenal insufficiency | Knockout mouse models; overexpression in cell lines |
| GNAS | Obesity, McCune-Albright syndrome | Point mutation knock-in in adipocytes |
| NR4A1 | Neuroinflammation | Knockout mice for intracerebral hemorrhage studies |
| ASIP | Pigmentation variation, melanoma risk | Overexpression in melanocytes |
Melanoma and skin cancer
MC1R variants that impair binding or signaling are associated with increased melanoma risk, particularly in individuals with fair skin and red hair. MC1R-targeted alpha-particle therapy has been explored for metastatic uveal melanoma, leveraging the receptor's expression on melanoma cells. Single-cell profiling of MC1R-inhibited melanocytes reveals transcriptional changes that may contribute to therapy resistance.
Neuroinflammation and brain injury
NDP-MSH binding to MC1R reduces neuroinflammation and blood-brain barrier disruption after intracerebral hemorrhage in mice, acting through the CREB/Nr4a1/NF-kB pathway. This suggests that MC1R agonists could be therapeutic for neuroinflammatory conditions.
Obesity and metabolic disorders
The melanocortin pathway, including MC1R and MC4R, is involved in energy homeostasis. Mutations in GNAS, which couples to melanocortin receptors, are associated with obesity, highlighting the importance of MC1R binding in metabolic regulation.
Adrenal disorders
ACTH binds to MC2R in the adrenal cortex to stimulate cortisol production, but it can also bind MC1R. Dysregulation of ACTH action is linked to adrenal insufficiency and Cushing's syndrome.
From type 1 melanocortin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MC1R binding mediate neuroprotection? | MC1R knockout mice treated with NDP-MSH |
| How do MC1R variants affect melanoma risk? | Point mutation knock-in of MC1R variants in melanocytes |
| What is the role of GNAS in melanocortin signaling? | GNAS point mutation knock-in in cell lines |
| Can MC1R be targeted for melanoma therapy? | MC1R overexpression in melanoma cells for binding assays |
| What genes are regulated by MC1R activation? | CRISPR knockout of MC1R followed by RNA-seq |
| How does ASIP antagonize MC1R? | Overexpression of ASIP in melanocytes |
How to Study the type 1 melanocortin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Binding affinity and receptor number | Characterizing MC1R-ligand interactions |
| cAMP assay | Intracellular cAMP levels | Measuring MC1R activation |
| Western blot | Protein phosphorylation (e.g., CREB) | Assessing downstream signaling |
| RNA-seq | Global gene expression changes | Identifying MC1R-regulated genes |
| Single-cell RNA-seq | Cell-to-cell variability in response | Profiling MC1R-inhibited melanocytes |
| CRISPR knockout screen | Genes required for MC1R signaling | Discovering novel pathway components |
| Immunofluorescence | Receptor localization and internalization | Studying MC1R trafficking |
| Alpha-particle therapy assay | Cytotoxicity of MC1R-targeted therapy | Evaluating therapeutic potential |
Binding assays
Radioligand binding assays using iodinated NDP-MSH or alpha-MSH can measure binding affinity and receptor density on cells expressing MC1R. These assays are fundamental to studying GO:0070996.
Signal transduction assays
cAMP accumulation assays and CREB phosphorylation Western blots are used to measure MC1R activation downstream of binding. These methods quantify functional consequences of ligand-receptor interaction.
Transcriptomics and single-cell profiling
RNA-seq and single-cell RNA-seq can reveal gene expression changes following MC1R binding or inhibition. Single-cell profiling of MC1R-inhibited melanocytes has identified distinct transcriptional states.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that modulate MC1R binding or signaling. These screens are powerful for discovering novel regulators of the pathway.
How CRISPR Can Be Used to Study GO:0070996 type 1 melanocortin receptor binding
Knockout
CRISPR knockout of MC1R in melanocytes or melanoma cells can abolish binding and downstream signaling, providing a clean background to study ligand specificity and pathway rewiring. Knockout of downstream effectors like CREB1 or NR4A1 can dissect their roles in MC1R-mediated neuroprotection.
Point Mutation
Introducing point mutations corresponding to natural MC1R variants (e.g., R151C, R160W) via CRISPR base editing or homology-directed repair allows functional assessment of binding affinity and signaling. Such models are valuable for understanding melanoma predisposition.
Knock-in
Knock-in of tagged MC1R (e.g., HA or GFP) enables visualization and biochemical isolation of the receptor. Knock-in of GNAS mutations can model obesity-associated signaling changes.
Overexpression
Overexpression of MC1R or its ligands (e.g., NDP-MSH) in cell lines can amplify signaling for biochemical assays. Overexpression of ASIP can mimic antagonism and study pigmentation regulation.
How EDITGENE Supports type 1 melanocortin receptor binding Research
Researchers studying type 1 melanocortin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR services to create precise genetic models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for type 1 melanocortin receptor binding research.
Frequently Asked Questions About type 1 melanocortin receptor binding
What is type 1 melanocortin receptor binding?
Type 1 melanocortin receptor binding (GO:0070996) is a molecular function where a ligand, such as alpha-MSH or NDP-MSH, binds to the MC1R receptor, initiating signaling cascades.
What genes are involved in type 1 melanocortin receptor binding?
Key genes include MC1R (the receptor), POMC (ligand precursor), ASIP (antagonist), and downstream effectors like CREB1 and NR4A1.
What diseases are associated with MC1R binding?
MC1R binding is linked to melanoma, neuroinflammation, obesity, and pigmentation disorders.
How can I study type 1 melanocortin receptor binding?
Common methods include radioligand binding assays, cAMP assays, Western blot, RNA-seq, and CRISPR screens.
What is the role of MC1R in melanoma?
MC1R variants that affect binding increase melanoma risk, and MC1R is a target for melanoma imaging and therapy.
Can CRISPR be used to study MC1R binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect MC1R function.
What is NDP-MSH?
NDP-MSH is a synthetic melanocortin analog that binds MC1R with high affinity and is used to study receptor activation and neuroprotection.
How does MC1R binding reduce neuroinflammation?
NDP-MSH binding to MC1R activates CREB and inhibits NF-kB, reducing neuroinflammation and blood-brain barrier disruption.
What are the downstream signals of MC1R binding?
MC1R binding activates Gs, increases cAMP, and triggers PKA/CREB signaling, as well as modulating NF-kB.
What cell models are available for MC1R research?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for MC1R and related genes.
Conclusion
Type 1 melanocortin receptor binding (GO:0070996) is a fundamental molecular event that initiates diverse physiological responses, from pigmentation to neuroprotection. Its dysregulation is implicated in melanoma, inflammatory diseases, and metabolic disorders. By leveraging CRISPR-based models and advanced screening technologies, researchers can uncover new insights into MC1R biology and develop targeted therapies. EDITGENE stands ready to support these efforts with custom cell models and bioinformatics solutions.
References
- 2. Toussi A et al.. 2020. Germline mutations predisposing to melanoma.. J Cutan Pathol 47(7):606-616 PMID: 32249949
- 3. Wu X et al.. 2019. NDP-MSH binding melanocortin-1 receptor ameliorates neuroinflammation and BBB disruption through CREB/Nr4a1/NF-κB pathway after intracerebral hemorrhage in mice.. J Neuroinflammation 16(1):192 PMID: 31660977
- 4. Mendes de Oliveira E et al.. 2021. Obesity-Associated GNAS Mutations and the Melanocortin Pathway.. N Engl J Med 385(17):1581-1592 PMID: 34614324
- 5. Feingold KR et al.. 2000. ACTH Action on the Adrenals.. PMID: 25905342
- 6. Tafreshi NK et al.. 2019. Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma.. J Nucl Med 60(8):1124-1133 PMID: 30733316
- 7. Agosti F et al.. 2017. Melanocortin 4 receptor constitutive activity inhibits L-type voltage-gated calcium channels in neurons.. Neuroscience 346:102-112 PMID: 28093215
- 8. Berns HM et al.. 2024. Single-cell profiling of MC1R-inhibited melanocytes.. Pigment Cell Melanoma Res 37(2):291-308 PMID: 37972124
